spacer
home > ict > spring 2021 > three challenges in creating plain language summaries of clinical trial results
PUBLICATIONS
International Clinical Trials

Three Challenges in Creating Plain Language Summaries of Clinical Trial Results



For years, the scientific community has prepped and planned for the production of plain language summaries (PLSs) of clinical trial results. As part of EU CTR 536/2014, sponsors must submit PLSs – i.e., documents that an average person without a scientific background could easily understand – of their trial results (1). The impetus behind this regulation has been the largely theoretical push for greater transparency. A 2019 Pharmaceutical Medicine article notes that: “Study participants, advocacy groups, and, to a lesser extent, the general public have called for greater transparency in their quest for information on clinical studies” (2).

Over the past year, the COVID-19 pandemic has underscored the demand for such transparency. This global pandemic has served as a case study in the importance of producing scientific information that the public can readily digest. As the world has collectively waited for COVID-19 vaccines and/or treatments, the results of clinical trials have become more interesting and relevant to non-scientific communities than ever before. As Parexel noted in a recent blog post: “Providing a PLS is even more crucial in this global health crisis, where in excess of 100 clinical research studies are being carried out to find a new drug – either to prevent or treat COVID-19” (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
About the Author


Wendy Farrell is the Senior Director of Content Development for RWS’s Regulated Industries division. In this role, she leads a team that creates and delivers compelling life science content, including articles, presentations, white papers, research, and thought leadership for professionals in highly regulated industries. With over 15 years spent in the localisation industry, Wendy has collaborated with experts and helped organisations build more meaningful connections with their global audiences, through her background in global marketing, sales, solution development, multimedia, and training.

Print this page
Send to a friend
Privacy statement
News and Press Releases

LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference

LivaNova PLC, a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place December 6 - 9 in Charleston, S.C.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement